10-Q: Vicarious Surgical Reports Q3 2024 Results, Net Losses Narrow Amid Cost Reductions

Vicarious Surgical reported a net loss of $17.1 million for the third quarter of 2024, an improvement compared to the $15.7 million loss in the same period last year, driven by reduced operating expenses.

Summary

• Vicarious Surgical, a company developing a surgical robotic system, reported its financial results for the quarter ended September 30, 2024.
• The company is pre-revenue and is focused on developing its surgical robot.
• The net loss for the quarter was $17.1 million, compared to a net loss of $15.7 million for the same period in 2023.
• The net loss for the nine months ended September 30, 2024 was $49.3 million, compared to $58.0 million for the same period in 2023.
• Operating expenses decreased by 17% in the third quarter and 21% for the nine-month period, primarily due to reduced personnel costs.
• Research and development expenses decreased by 17% in the third quarter and 19% for the nine-month period.
• Sales and marketing expenses decreased by 14% in the third quarter and 29% for the nine-month period.
• General and administrative expenses decreased by 17% in the third quarter and 22% for the nine-month period.
• The company's cash and cash equivalents and short-term investments totaled $60.9 million as of September 30, 2024.
• Management believes the current cash balance will support operations for the next twelve months, but additional capital will be needed for commercialization.
• The company is pursuing FDA authorization for its surgical system, with a de novo application planned for ventral hernia procedures as the first indication.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company is still incurring losses and needs to raise capital, it has shown improvement in cost management and has regained compliance with NYSE listing requirements. The company also has a clear regulatory strategy and is moving forward with its product development.

Positives

• The company's net loss decreased in the third quarter of 2024 compared to the same period in 2023.
• Operating expenses have been significantly reduced, indicating improved cost management.
• The company has regained compliance with NYSE listing requirements, removing a potential delisting risk.
• The company has a clear regulatory strategy and is planning to file a de novo application with the FDA.
• The company has a cash balance of $60.9 million, which is expected to support operations for the next twelve months.

Negatives

• The company is still pre-revenue and continues to incur significant net losses.
• The company will need to raise additional capital to complete the development and commercialization of its product.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company's future success is dependent on obtaining FDA authorization for its surgical system.

Risks

• The company is pre-revenue and may not generate revenue until FDA authorization is received.
• The company will need to raise additional capital to fund its operations and commercialization efforts.
• The company's success depends on the successful development and commercialization of its surgical robot.
• The company faces competition from other companies in the surgical robotics market.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company's stock price may be volatile and subject to market fluctuations.

Future Outlook

The company expects to continue to incur net losses as it invests in commercialization and new product development. Management believes the current cash balance will support operations for the next twelve months, but additional capital will be needed for commercialization. The company plans to file a de novo application with the FDA for use in ventral hernia procedures as its first indication.

Management Comments

• Management believes that the company's current cash, cash equivalents and short-term investments balance will be sufficient to support operations beyond the next twelve months.
• Management acknowledges that additional capital will be needed to complete the development and commercialization of the product.
• Management is focused on designing and implementing effective internal controls measures to improve the evaluation of disclosure controls and procedures.

Industry Context

The company is developing a surgical robotic system to address the limitations of open surgery and existing robotic surgical approaches. The market for surgical robotics is growing, but adoption has been slow due to high costs, low utilization, limited capabilities, and difficulty of use. Vicarious Surgical aims to overcome these limitations with its single-port system.

Comparison to Industry Standards

• Vicarious Surgical is competing in the surgical robotics market, which includes established players like Intuitive Surgical (ISRG) with its da Vinci system, and Medtronic (MDT) which has been expanding its robotic surgery portfolio.
• Intuitive Surgical's da Vinci system is a multi-port system, while Vicarious Surgical is developing a single-port system, which is intended to be less invasive.
• The company's focus on ventral hernia procedures as its first indication is a strategic move to target a specific market segment.
• The company's financial results show a reduction in operating expenses, which is a positive sign compared to other early-stage companies in the industry that often struggle with high burn rates.
• The company's need for additional capital is typical for companies in the medical device industry, especially those developing complex technologies like surgical robots.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Employees may be affected by the company's cost-cutting measures, including reduced headcount.
• Customers (hospitals and surgeons) will be impacted by the availability and performance of the company's surgical robot.
• Suppliers may be affected by the company's production and supply chain decisions.
• Creditors may be affected by the company's ability to repay its debts.

Next Steps

• The company plans to file a de novo application with the FDA for use in ventral hernia procedures.
• The company will continue to develop and refine its surgical robotic system.
• The company will need to raise additional capital to fund its operations and commercialization efforts.
• The company will continue to work on remediating the material weaknesses in its internal control over financial reporting.

Key Dates

Keywords

surgical robotics, minimally invasive surgery, FDA authorization, net loss, operating expenses, research and development, capital raise, NYSE compliance, warrant liabilities, internal control